Ligand Pharmaceuticals Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Scott Plesha

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	14.5yrs

Actualizaciones recientes de la dirección

Recent updates

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17

Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year

Dec 31

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Dec 03

Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?

Oct 11

CEO

Scott Plesha (58 yo)

less than a year

Permanencia

Mr. Scott M. Plesha is Chief Executive Officer of Ligand Pharmaceuticals Incorporated from April 2024. Mr. Plesha had been the President of BioDelivery Sciences International, Inc. since December 2017 and...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Matthew Korenberg	President & COO	1.5yrs	US$3.59m	0.39% $ 5.6m
Octavio Espinoza	Chief Financial Officer	1.5yrs	US$2.45m	0.054% $ 775.1k
Andrew Reardon	Chief Legal Officer & Secretary	1.5yrs	US$2.34m	0.031% $ 441.9k
Scott Plesha	Chief Executive Officer	less than a year	sin datos	sin datos
Paul Hadden	Senior Vice President of Investments & Business Development	no data	sin datos	sin datos
Simon Latimer	Head of Investor Relations	no data	sin datos	sin datos
Todd Pettingill	Director of Corporate Development	no data	sin datos	sin datos
Audrey Warfield-Graham	Chief People Officer	17.3yrs	sin datos	sin datos
Keith Marschke	Senior Vice President of Biology & Scientific Affairs	6.3yrs	sin datos	sin datos
Vincent Antle	Senior Vice President of Technical Operations & QA - Capitsol	6.3yrs	sin datos	sin datos
Patrick Lucy	Senior VP & CBO Protein Expression Business	no data	sin datos	sin datos
Karen Reeves	Senior VP of Clinical Strategy & Investments	less than a year	sin datos	sin datos

1.5yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LGND no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Kozarich	Independent Chairman	21.2yrs	US$361.70k	0.23% $ 3.3m
Todd Davis	Director	17.2yrs	US$6.22m	0.43% $ 6.1m
John LaMattina	Independent Director	13.3yrs	US$329.20k	0.16% $ 2.3m
Stephen Sabba	Independent Director	15.8yrs	US$341.70k	0.16% $ 2.3m
Jason Aryeh	Independent Director	17.7yrs	US$339.20k	0.45% $ 6.5m
Shalendar Bhasin	Scientific Advisor	no data	sin datos	sin datos
Jason Haas	Independent Director	1.9yrs	US$346.70k	0.012% $ 172.3k
Nancy Gray	Independent Director	6.8yrs	US$336.70k	0.037% $ 527.8k
Martine Zimmermann	Independent Director	less than a year	US$467.87k	sin datos

14.5yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de LGND son experimentados ( 14.4 años antigüedad media).

Ligand Pharmaceuticals Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 14, 2024

CEO & Director exercised options to buy US$1.2m worth of stock.

Chief Financial Officer notifies of intention to sell stock

Ligand Pharmaceuticals Incorporated Announces Management Appointments

CEO & Director recently bought US$238k worth of stock

Ligand Pharmaceuticals Incorporated Appoints Martine Zimmermann to its Board of Directors

Recent updates

First quarter 2024 earnings released: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 14, 2024

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

CEO & Director exercised options to buy US$1.2m worth of stock.

Chief Financial Officer notifies of intention to sell stock

Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Announces Management Appointments

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 28%, revenue upgraded

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ligand Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

CEO & Director recently bought US$238k worth of stock

Ligand Pharmaceuticals Incorporated Appoints Martine Zimmermann to its Board of Directors

Ligand Pharmaceuticals Incorporated Reaffirms Revenue Guidance for 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) announces an Equity Buyback for $50 million worth of its shares.

Ligand's Collaborator Merck Announces V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Ligand Pharmaceuticals Incorporated to Report Q2, 2023 Results on Aug 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a stalking horse asset purchase agreement to acquire Substantially All of the Assets of Novan, Inc. for $15 million.

Consensus EPS estimates increase by 73%

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Independent Chairman recently sold US$343k worth of stock

Independent Chairman notifies of intention to sell stock

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

Ligand Pharmaceuticals Incorporated Raises Earnings Guidance for 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 41%

Full year 2022 earnings released: US$0.31 loss per share (vs US$3.44 profit in FY 2021)

Ligand Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 22, 2023

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Executive Director notifies of intention to sell stock

Executive Director exercised options to buy US$998k worth of stock.

Ligand Pharmaceuticals Incorporated Announces CEO Changes

Price target decreased to US$111

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%

Insufficient new directors

Chief Financial Officer recently sold US$128k worth of stock

Price target decreased to US$131

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Year 2022

Insufficient new directors

Ligand Pharmaceuticals Incorporated Appoints Octavio (Tavo) Espinoza as Chief Financial Officer

Ligand Pharmaceuticals Incorporated to Report Q3, 2022 Results on Nov 07, 2022

Price target decreased to US$149

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

CEO & Executive Director notifies of intention to sell stock

CEO & Executive Director recently sold US$180k worth of stock

Consensus estimates of losses per share improve by 14%

Consensus revenue estimates increase by 11%

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Full Year 2022

Ligand Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 08, 2022

Ligand Pharmaceuticals Incorporated Appoints Jason Haas to its Board of Directors

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Investor sentiment improved over the past week

Consensus forecasts updated